Skip to content

Early Integration of Palliative and Supportive Care in Cellular Therapy

Lymphoma | Multiple Myeloma | Leukemia | Stem Cell Transplant Complications | Blood...

Research has shown that early palliative care in cancer care is associated with improved symptom management, better prognostic understanding, improved quality of life for patients and family caregivers, and even improved survival. Yet, in spite of the proven benefits of integration of palliative care in oncology, it has been well established that patients with hematologic malignancies and those undergoing cellular therapy (hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor (CAR) T-cell therapy) do not routinely receive palliative care. Most of the published research on the early integration of palliative care in oncology describes studies that have involved patients with solid tumours. To date, only one randomized trial examining the impact of integrated palliative care among patients undergoing HSCT has been published and there have been no studies examining the impact of integrated palliative care for patients undergoing CAR T-cell therapy. The American Society of Clinical Oncology recommends early palliative care for patients with advanced cancers or for those with high symptom burden. Patients with blood cancers experience high symptom burden and in the last 30 days of life, compared to patients with solid tumours, patients with blood cancers are more likely to die in hospital, have more intensive care unit admissions, have prolonged hospitalizations (\>14 days), and pass away in an acute care facility. There is an urgent need to proactively address suffering throughout cellular therapy trajectories, even before treatment starts, so that patients and caregivers are not inevitably waiting for symptoms to arise before they can be addressed and to optimize quality of life for patients undergoing transplant as well as their family caregivers.

PALS_CT will compare early palliative care to standard care for patients and their family caregivers undergoing HSCT or CAR T-cell therapy for blood cancers.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria - Patients

* Clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy
* Ability to speak, read, and understand English or, be able to complete questionnaires with minimal assistance required from an interpreter

Inclusion Criteria - Family Caregivers

* Family caregivers of patients with a clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy
* A spouse, relative, or friend, identified by the patient, who either lives with the patient or has in-person contact with the patient at least twice per week. Only one family CG per patient will be asked to participate.
* Ability to speak, read, and understand English or willing to complete questionnaires with minimal assistance required from an interpreter

Exclusion Criteria - Patients

* Patients undergoing HSCT for a non-malignant hematologic condition
* Inability to provide informed consent

Exclusion Criterion - Family Caregivers

\* Inability to provide informed consent

Lieu de l'étude

Tom Baker Cancer Centre
Tom Baker Cancer Centre
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Don Morris, MD PhD

403-521-370
Étude parrainée par
Alberta Health Services, Calgary
Participants recherchés
Plus d'informations
ID de l'étude: NCT05190653